Company News Summary | 04 Dec 2019
Click the print icon in your browser to print this report. Currency is in AUD unless otherwise specified
CSL Provides Annual Research And Development Investor Briefing
08:39:00 | Associate analysts
Original annuncemenet:Research and Development Investor Briefing 2019
CSL provided 2019 annual research and development investor briefing. It reported on activities focused on new therapies for life-threatening diseases. The Company noted that Haptoglobin Prevents Vasospasms Induced by Haemorrhagic CSF. CSL346 is a novel humanised monoclonal antibody (IgG4) that binds VEGF-B.
|This report appeared on www.morningstar.com.au||2020 Morningstar Australasia Pty Limited|
© Copyright 2020 Morningstar Australasia Pty Ltd ABN: 95 090 665 544 ("Morningstar"), AFSL no 240892. (a subsidiary of Morningstar, Inc.). This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written content of Morningstar. Some of the material provided is published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO").